L'Oréal (ENXTPA:OR) has drawn investor attention after announcing a multi year research partnership with NUS Medicine in Singapore, focused on longevity science and a joint lab for skin, scalp and hair.
See our latest analysis for L'Oréal.
L'Oréal's recent longevity partnership comes as the stock shows steady but unspectacular momentum, with a 90 day share price return of 7.34% and a 1 year total shareholder return of 0.54%. This suggests that expectations are firming rather than surging.
If this kind of science led story has your attention, it might be a good moment to widen your watchlist and check out 103 top founder-led companies
L'Oréal now has a fresh longevity story and a modest recent return profile, which puts you between two options. Do you pay up today for that research pipeline, or wait and hope the price gives you another shot?
Most Popular Narrative: 8.1% Undervalued
L'Oréal's most followed valuation narrative points to a fair value of €417.08 compared with a last close of €383.30, which frames this longevity partnership against a stock already priced with moderate upside in mind.
Ongoing rapid shift to online channels, e-commerce accounted for nearly 29% of first-half sales and is growing at double the pace of the market, enhances direct-to-consumer margins and customer acquisition efficiency, bolstering both profitability and top-line expansion.
Want to see what sits behind that e-commerce driven fair value for L'Oréal? The narrative leans on steady revenue compounding, firmer margins and a rich profit multiple that still assumes investors keep paying up for quality beauty earnings. It also considers which specific growth and margin paths would need to align for that price target to hold.
Result: Fair Value of €417.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the L'Oréal story could look very different if competition in China intensifies or if higher marketing spend fails to translate into the expected sales growth.
Find out about the key risks to this L'Oréal narrative.
Another View On L'Oréal’s Valuation
The first story on L'Oréal leans on a fair value of €417.08 and an 8.1% discount using future earnings assumptions. On plain P/E, the picture looks less relaxed. The stock trades on 32.4x earnings compared with 26.7x for peers and 17x for the wider European personal products industry, even though the fair ratio is 33x. That leaves very little room for disappointment if growth or margins do not line up with the narrative.
To see how this premium multiple stacks up against the underlying numbers, and what that gap could mean if the market shifts back toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Feeling encouraged by the tone around L'Oréal so far but still undecided. Consider acting promptly: review the underlying data yourself, then weigh those 3 key rewards
Looking For More Ideas Beyond L'Oréal?
If L'Oréal has sharpened your focus, do not stop here. Broader ideas can help you cross check assumptions, spot outliers and pressure test your conviction.
- Target dependable income and stress test your yield expectations by reviewing the 445 dividend fortresses.
- Hunt for quality at a sensible price and compare L'Oréal with the companies in the screener containing 602 high quality undiscovered gems.
- Prioritise staying power and see how sturdier balance sheets look beside L'Oréal by scanning the solid balance sheet and fundamentals stocks screener (432 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com